Lexicon Pharmaceuticals | LXRX - Current Assets


Lexicon Pharmaceuticals reported $186.03M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Abbott USD 25.51B 488M Mar/2026
Acadia Pharmaceuticals USD 1.1B 33.9M Mar/2026
Agios Pharmaceuticals USD 834.84M 107.21M Mar/2026
Akebia Therapeutics USD 243.48M 9.47M Mar/2026
Alnylam Pharmaceuticals USD 4.22B 168.65M Mar/2026
AstraZeneca USD 29.61B 890M Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Coherus Biosciences USD 206.71M 254.25M Dec/2025
Eli Lilly USD 54.84B 794M Mar/2026
Esperion Therapeutics USD 459.46M 3.11M Mar/2026
Halozyme Therapeutics USD 1B 177.83M Mar/2026
Illumina USD 2.74B 551M Mar/2026
Insmed USD 1.61B 181.04M Mar/2026
Ironwood Pharmaceuticals USD 332.29M 58.11M Mar/2026
J&J USD 59.17B 3.55B Mar/2026
Lexicon Pharmaceuticals USD 186.03M 84.14M Mar/2026
MacroGenics USD 182.52M 37.42M Mar/2026
MannKind USD 251.16M 40.42M Mar/2026
Merck USD 35.02B 8.5B Mar/2026
Moderna USD 5.77B 774M Mar/2026
Novartis USD 26.61B 3.85B Mar/2026
PTC Therapeutics USD 2.25B 19.94M Mar/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
Thermo Fisher Scientific USD 22.32B 6.39B Mar/2026
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
United Therapeutics USD 2.87B 830.5M Mar/2026
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025